VolitionRX aims for cash flow neutrality in 2025 as human diagnostics licensing advances VolitionRX aims for cash flow neutrality in 2025 as human diagnostics licensing advances Post ContentvnrxRead More You might also be interested in reading NuCana receives compliance notification from Nasdaq. May 16, 2025 In Mainstream ← Previous post Next post →